<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVE: Marrow transplantation results in disease-free survival for less than one-third of patients treated for secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The objective of this report is to review results following allogeneic marrow transplantation for treatment of secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> at a single tertiary referral center to determine the patient characteristics which lead to better survival and lower relapse </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN AND METHODS: The medical records of 99 patients with secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> transplanted consecutively at the Fred Hutchinson <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Research Center between 1971 and 1997 were reviewed </plain></SENT>
<SENT sid="3" pm="."><plain>Prior to development of secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, the patients' original diagnoses were <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e>, <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, or miscellaneous individual disorders previously treated by chemotherapy alone, radiation alone, chemoradiotherapy, or immunosuppressive therapy </plain></SENT>
<SENT sid="4" pm="."><plain>At the time of transplantation, at each stage of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> the numbers of patients were 52 with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 15 with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transition (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>), 18 with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), 11 with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), 1 with <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), and 2 with hypoplastic unclassifiable <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Sixty-five patients received marrow from an HLA identical or partially identical family member, and 34 received marrow from an HLA identical unrelated donor after conditioning with chemotherapy and total body irradiation or chemotherapy alone </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The Kaplan-Meier probability of survival after transplantation for <z:hpo ids='HP_0000001'>all</z:hpo> patients was 13%, and by stage of disease was 33% for RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, 20% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, and 8% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The probability of relapse for <z:hpo ids='HP_0000001'>all</z:hpo> patients was 47%, was 34% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, and 58% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>None of the patients with RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> has relapsed </plain></SENT>
<SENT sid="9" pm="."><plain>The overall probability of non-relapse mortality was 78%, divided equally among <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> or organ failure-related causes of <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>INTERPRETATION AND CONCLUSIONS: The main impediments to long-term survival after transplantation for secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> are relapse and mortality from <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> or organ failure </plain></SENT>
<SENT sid="11" pm="."><plain>The survival is better when transplantation is done during the early stages of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> because it is then associated with a lower relapse rate </plain></SENT>
<SENT sid="12" pm="."><plain>These data suggest that patients at risk of secondary <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> should be followed prospectively to detect the early stages of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, and be considered for transplantation at that time </plain></SENT>
</text></document>